Explore the words cloud of the Ovage project. It provides you a very rough idea of what is the project "Ovage" about.
The following table provides information about the project.
|Coordinator Country||Italy [IT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
|Duration (year-month-day)||from 2017-08-01 to 2018-01-31|
Take a look of project's partnership.
OvAge s.r.l. is the owner of a pioneering patented medical device-software able in quantifying women ovarian reserve (both in term of fertility potential and distance to menopause) by integrating clinical, biochemical and 3D-ultrasonographic data. For the first time in this field of medicine, this instrument, also called OvAge®, gives as a result explicitly the ovarian age of a woman, a ready-to-use information that is going to revolutionize the relationship of women with themselves and with the Specialists in the field of Gynaecology. OvAge s.r.l. objective is to diffuse its innovative research product all over the world, with the purpose of helping both women (healthy or affected by infertility, benign or malignant pathologies) and physicians (general and specialists) in the management of many frequent conditions affecting the reproductive life of a woman. In this way, OvAge® aims to contribute the sustainability of health care systems, by reducing both costs related to late diagnosis of infertility and those related to useless surgeries in women affected by benign pathologies for which menopause is the best and cheaper therapy. Moreover, OvAge® will solve women needs for life planning by predicting reproductive potential and for safely solving common pathologies by predicting distance to menopause. To reach these goals, a feasibility study is needed. It will produce a market study for each European member state,proposals on best practice to enhance customer loyalty, a risk assessment of the plan and a potential licensing in order to launch OvAge® software medical device in the EU market initially through a web site. Later, OvAge s.r.l. aim to commercialize its product in the rest of the world (phase 2) as a medical hardware device. The most relevant market segment for OvAge® is the population of women residents in all EU countries, although our challenges and markets are global, since infertility and female pathologies are the same in all parts of the world.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVAGE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "OVAGE" are provided by the European Opendata Portal: CORDIS opendata.
CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical researchRead More
SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.Read More
Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneouslyRead More